United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $592.42, for a total transaction of $5,627,990.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $192,206,522.06. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $584.10 on Wednesday. United Therapeutics Corporation has a 52 week low of $455.63 and a 52 week high of $614.23. The firm has a 50-day moving average price of $546.33 and a two-hundred day moving average price of $537.56. The firm has a market cap of $24.88 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 3.91 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The business had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.16 EPS. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 25.08 earnings per share for the current year.

United Therapeutics announced that its Board of Directors has approved a share buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Toth Financial Advisory Corp grew its position in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics during the second quarter worth approximately $30,000. Gen Wealth Partners Inc bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $34,000. Caitlin John LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $37,000. Finally, International Assets Investment Management LLC lifted its holdings in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 64 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on UTHR. The Goldman Sachs Group restated a “sell” rating and issued a $368.00 price objective on shares of United Therapeutics in a research note on Thursday, October 15th. Leerink Partners raised their target price on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. UBS Group set a $725.00 target price on United Therapeutics in a research note on Monday, October 19th. Raymond James Financial set a $720.00 price target on shares of United Therapeutics in a report on Wednesday, November 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $850.00 price target on shares of United Therapeutics in a research report on Monday, October 26th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $676.40.

Check Out Our Latest Stock Report on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.